Royal Bank of Canada Buys 141,517 Shares of Enovis Co. (NYSE:ENOV)

Royal Bank of Canada boosted its holdings in shares of Enovis Co. (NYSE:ENOV - Free Report) by 25.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 707,361 shares of the company's stock after buying an additional 141,517 shares during the period. Royal Bank of Canada owned about 1.24% of Enovis worth $31,038,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Aster Capital Management DIFC Ltd acquired a new stake in shares of Enovis during the fourth quarter worth approximately $29,000. Quadrant Capital Group LLC increased its holdings in shares of Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after buying an additional 239 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after buying an additional 437 shares in the last quarter. Quarry LP increased its holdings in shares of Enovis by 506.1% during the fourth quarter. Quarry LP now owns 897 shares of the company's stock worth $39,000 after buying an additional 749 shares in the last quarter. Finally, Sterling Capital Management LLC increased its holdings in shares of Enovis by 56.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,259 shares of the company's stock worth $143,000 after buying an additional 1,173 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.

Wall Street Analysts Forecast Growth

ENOV has been the subject of several recent analyst reports. Canaccord Genuity Group dropped their price objective on shares of Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Needham & Company LLC reduced their price target on shares of Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. Finally, JMP Securities reduced their price target on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $58.00.

Enovis Trading Down 2.0%

NYSE:ENOV traded down $0.67 on Wednesday, hitting $32.77. 482,642 shares of the stock were exchanged, compared to its average volume of 1,006,366. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -14.98 and a beta of 1.79. Enovis Co. has a 52 week low of $29.32 and a 52 week high of $51.00. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The company's 50-day moving average price is $34.45 and its 200 day moving average price is $40.86.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.07. The firm had revenue of $558.83 million during the quarter, compared to analysts' expectations of $558.80 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company's quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.50 EPS. On average, equities research analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.